Rapidscan Pharma Solutions Inc. has been acquired by GE Healthcare

December 2016 — The shareholders of Rapidscan Pharma Solutions, Inc. (Rapidscan) have sold the company to GE Healthcare, a global provider of contrast media, medical technologies and services, and biomanufacturing solutions. Financial details have not been disclosed.

Rapidscan is a privately held healthcare company specializing in the production of Rapiscan®, a selective coronary vasodilator for radionuclide myocardial perfusion imaging. The company was founded in 2010 by leading members of the team that discovered and developed regadenoson, a new pharmacological stress agent used in the diagnosis and risk stratification of cardiovascular disease.

Headquartered in Chicago, GE Healthcare is a unit of General Electric Company (NYSE: GE). GE Healthcare is a global provider of contrast media, medical technologies and services, and biomanufacturing solutions. GE Healthcare has acquired the exclusive rights from Rapidscan to produce and sell the pharmacological stress agent Rapiscan® (Regadenoson) in territories outside the USA, Canada and Mexico.

Our role in the transaction

Oaklins Cavendish, based in the UK, advised Radpidscan on its acquisition by GE Healthcare. Oaklins Cavendish has considerable experience in advising pharmaceutical and healthcare businesses. The team's specialist commented: “We are delighted to have advised the shareholders of Rapidscan and to have found in GE Healthcare the right buyer to continue to expand Rapidscan’s growing network of markets outside of North America. This acquisition will see Rapidscan and GE Healthcare unlock significant synergies from their complementary geographical reach and will meet the growing demand for Rapidscan’s specialist product.”